Reversing multidrug resistance by tyrosine kinase inhibitors - Wikidata - awgldk - TriplyDB

Reversing multidrug resistance by tyrosine kinase inhibitors

Reversing multidrug resistance by tyrosine kinase inhibitors

http://www.wikidata.org/entity/Q37183670

about

Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy

P2860

Q26775004-2FECBC5E-9704-429A-8C5C-3B8A032AB9BB Q33590428-1A5CAD34-3FE9-48A9-BE43-BCA41CD9EF3B Q35109273-4248EEB3-EAB0-4653-8B6B-BE5838D69E7D Q36462972-295C5C58-4D00-46F3-AA7C-C50E0397B2F7 Q36562186-21357C3F-831B-4450-B27E-CF4C840D430F Q38246305-0A635AA8-9C4A-4B98-9E0E-297338E229E5 Q41514180-33863123-4B59-45B6-ACBA-26F7BF1DDA9B Q41660826-B9CFFD78-8E92-4240-B9B0-94020F7C7796 Q45711840-55ED85EA-025E-42E8-BB4C-DE9199C4E599 Q46028686-A634BC20-08AA-4C34-8E75-18D6B6FA7CEF Q49887925-99EEC8DE-C9B8-4051-B399-6DCD0DF169EE Q50784573-5B48BE70-1393-407D-94F6-A63677258051 Q58709993-7E60CBBB-AD5E-4839-81F0-70AC329CD944

P2860

Reversing multidrug resistance by tyrosine kinase inhibitors

http://www.wikidata.org/entity/Q37183670

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 January 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reversing multidrug resistance by tyrosine kinase inhibitors

@en

Reversing multidrug resistance by tyrosine kinase inhibitors.

@nl

type

label

Reversing multidrug resistance by tyrosine kinase inhibitors

@en

Reversing multidrug resistance by tyrosine kinase inhibitors.

@nl

prefLabel

Reversing multidrug resistance by tyrosine kinase inhibitors

@en

Reversing multidrug resistance by tyrosine kinase inhibitors.

@nl

P1433

Q37183670-C0702725-2600-42BE-8073-C16ADD14498F

P1476

Q37183670-1B95BBD6-2E97-48C2-A7EF-978972A4AE1F

P2093

Q37183670-07E6890E-6C07-4C49-83C6-57318D1B130D

Q37183670-84EDCB13-D006-4762-9A94-6B5482888175

P275

Q37183670-60893007-1C94-4C6F-AF0F-B22C4639ED56

P2860

Q37183670-0057F94A-F989-4CC7-8A39-B5705CB8FBB5

Q37183670-023A18C2-DF18-40C6-8E57-41D378193D75

Q37183670-03889636-500A-4F19-AA9E-75A72E9A416B

Q37183670-03AC242C-8436-447D-A3EC-C0EB65363228

Q37183670-04299DD3-05B4-4C70-947E-4D8506261D30

Q37183670-0D281150-DAE7-4BEB-B4AF-84B3F7672894

Q37183670-1A2D18FB-6508-44EC-B97C-B30F809F4ED1

Q37183670-1B306ABE-4E0D-4CA6-ABC7-0BA123FB49FC

Q37183670-2627203D-3415-4C08-8345-E539E18A69F1

Q37183670-2F511AE5-57D2-46B8-8B53-3D47EBB15231

P304

Q37183670-340B7A8F-FEC9-4E8F-B873-127638EAEF34

P31

Q37183670-B6C9A458-1EA8-4583-A1AA-4A76223286E7

Q37183670-E3CA29D4-512C-4E4C-8CB5-19E2B6589973

P356

Q37183670-48123189-A42D-4C20-AA4B-F6404DD7811F

P433

Q37183670-DD85AC39-F717-4F9F-A65C-ADAE8DADA044

P478

Q37183670-39703217-5A0C-4EBE-A9BF-DB4E36783E50

P5008

Q37183670-71FD9234-B290-4993-A7C7-BF30D3385F6F

P577

Q37183670-3998A87A-D1D6-46E0-92A5-731A8395BA20

Q37183670-5E505DE2-26A1-4C0E-9197-8BA7011DBB9B

P5875

Q37183670-AA23B001-9CAE-4258-8F03-2B776654BB97

P698

Q37183670-946705F3-3B7F-4B62-AAE8-00E77FDB3E4D

P921

Q37183670-47AFF118-C3F2-4348-8D6E-E6A4C311CEF4

Q37183670-6FF1E89A-FD63-4773-97D5-66F11ED2D0F4

Q37183670-773E8C73-4F43-4018-8FA2-342E0F4ED4EB

Q37183670-8E51CD65-2CEE-4277-898A-01C434F70D4F

Q37183670-A8C03E80-97C4-4652-ACF2-543DB71E92EC

Q37183670-E595B4F5-013E-4B65-887C-F4A20A94D5D7

P932

Q37183670-3D74E837-A726-45D6-BD1D-00296081C288

P356

P1433

Chinese Journal of Cancer

P1476

Reversing multidrug resistance by tyrosine kinase inhibitors

@en

P2093

Miao He

http://www.w3.org/2001/XMLSchema#string

Min-Jie Wei

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

P2860

Cell signaling by receptor tyrosine kinases

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

The protein tyrosine kinase family of the human genome

Oncogenic kinase signalling

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

P304

126-133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5732/CJC.011.10315

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2012-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221740280

http://www.w3.org/2001/XMLSchema#string

P698

22237041

http://www.w3.org/2001/XMLSchema#string

P921

transport protein

mechanism of action

membrane proteins

multiple drug resistance

P932

3777484

http://www.w3.org/2001/XMLSchema#string